NICE recommends the Genedrive® CYP2C19-ID Kit
Abingdon Health PLC (AIM:ABDX) Design freeze completion & strategic partnership
Four sexually transmitted disease lateral flow self-tests complete design freeze.
Abingdon Health PLC (AIM:ABDX) Launch of OEM self-tests in Boots
Launch of OEM self-tests in Boots
Abingdon Health PLC (AIM:ABDX) Interim Results
Interim Results for the six months ended 31 December 2023
Genedrive PLC (AIM:GDR) Initial overseas orders of MT-RNR1 ID kit
Initial overseas orders of the Genedrive® MT-RNR1 ID Kit
Abingdon Health PLC (AIM:ABDX) Final Results
York, U.K. 17 October 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces its final results for the
Abingdon Health PLC (AIM:ABDX) Salistick™ to be launched in Tesco
Salistick™, the first ever saliva pregnancy test, to be launched in Tesco
Abingdon Health PLC (AIM:ABDX) Launch of Salistick™ saliva pregnancy test
Superdrug to sell Salistick™, the first ever saliva pregnancy test, initially in 400 stores and online Salistick™ also to launch on the Abingdon Simply Test website
Genedrive PLC (AIM:GDR) Multi-partner grant awarded
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive PLC – NICE recommends CYP2C19 genotyping
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Abingdon Health PLC (AIM:ABDX) Senzo and Abingdon Health enter into strategic partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month